Physician profile
Scott Cohen
NPI 1346431095
$1,248.22
in general payments reported to CMS, 2019-2025
18 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $91.10 · 2021: $91.00 · 2022: $121 · 2023: $117 · 2024: $207 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437 · Education: $19.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.97 |
| Education | $19.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $286.99 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $202.93 | 2019 | |
| Glaxosmithkline, LLC. | $128.38 | 2019-2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $120.86 | 2022 | |
| Travere Therapeutics, INC. | $119.85 | 2024-2025 | Filspari |
| Calliditas Therapeutics US INC. | $103.72 | 2024-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $52.99 | 2025 | |
| Mylan Specialty L.P. | $44.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.00 | 2019 | |
| Genzyme Corporation | $24.98 | 2019 | |
| Astellas Pharma US INC | $23.76 | 2021 | |
| Organogenesis INC. | $23.70 | 2025 | Puraply Wound Matrix |
| Actelion Pharmaceuticals US, INC. | $22.14 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.92 | 2025 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $11.20 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.